CCS AI Platform Enhances CGM Adherence, Saves Over $10M in Medicare Diabetes Care
CCS, a company providing clinical solutions and home-delivered medical supplies for chronic conditions, reports significant success with its AI-powered predictive analytics platform, PropheSee™, in improving continuous glucose monitoring (CGM) adherence among Medicare fee-for-service patients with diabetes. PropheSee™ identifies patients at risk of CGM nonadherence with an 85% accuracy rate, enabling early intervention through personalized, data-driven strategies tailored to patient-specific clinical and socioeconomic factors. This intervention has improved CGM adherence in over a third of the high-risk Medicare population, generating over $10 million in taxpayer savings by reducing unused devices and preventing costly complications.
The platform's predictive capabilities allow healthcare providers and payers to proactively manage patient adherence, potentially improving clinical outcomes and lowering high-cost healthcare utilization such as emergency room visits. CCS emphasizes the role of suppliers in advancing value-based, proactive chronic care management, integrating medical devices, pharmaceuticals, and clinical education into a comprehensive care model. Independent studies published by CCS highlight superior patient outcomes when suppliers provide clinical coaching alongside CGM support compared to traditional pharmacy models.
Industry leaders recognize the shift toward preventive care facilitated by AI-driven tools like PropheSee™, underscoring the opportunities for health plans and providers to prevent care crises among complex, high-cost populations. CCS plans to expand its role as an integrated chronic care management platform, utilizing machine learning and large language models to further optimize patient identification and engagement in the Medicare population.
Overall, CCS’s innovative application of AI in chronic care highlights a growing trend in healthcare management where predictive analytics, personalized intervention, and supplier-based education converge to reduce costs and enhance care quality for patients with diabetes. This approach aligns with broader industry goals of transitioning from reactive to preventive care models, particularly within high-risk Medicare groups.